These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32152677)

  • 61. Influence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort.
    Wolter S; Duprée A; Coelius C; El Gammal A; Kluwe J; Sauer N; Mann O
    Obes Surg; 2017 Jan; 27(1):90-95. PubMed ID: 27272667
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Revised sleeve gastrectomy: another option for weight loss failure after sleeve gastrectomy.
    Noel P; Nedelcu M; Nocca D; Schneck AS; Gugenheim J; Iannelli A; Gagner M
    Surg Endosc; 2014 Apr; 28(4):1096-102. PubMed ID: 24170068
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency.
    Luger M; Kruschitz R; Kienbacher C; Traussnigg S; Langer FB; Schindler K; Würger T; Wrba F; Trauner M; Prager G; Ludvik B
    Obes Surg; 2016 Oct; 26(10):2425-32. PubMed ID: 26989059
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Effect of Laparoscopic Sleeve Gastrectomy on Obesity and Obesity-related Disease : the Results of 10 Initial Cases.
    Kashihara H; Shimada M; Yoshikawa K; Higashijima J; Miyatani T; Tokunaga T; Nishi M; Takasu C; Hamada Y
    J Med Invest; 2019; 66(3.4):289-292. PubMed ID: 31656291
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease.
    Batman B; Altun H; Simsek B; Aslan E; Namli Koc S
    Surg Laparosc Endosc Percutan Tech; 2019 Dec; 29(6):509-512. PubMed ID: 31107849
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).
    D'Ambrosio R; Campi I; Maggioni M; Perbellini R; Giammona E; Stucchi R; Borghi M; Degasperi E; De Silvestri A; Persani L; Fugazzola L; Lampertico P
    PLoS One; 2021; 16(4):e0249614. PubMed ID: 33822817
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Utility of Multiparametric CT for Identification of High-Risk NAFLD.
    Lubner MG; Graffy PM; Said A; Watson R; Zea R; Malecki KM; Pickhardt PJ
    AJR Am J Roentgenol; 2021 Mar; 216(3):659-668. PubMed ID: 33474981
    [No Abstract]   [Full Text] [Related]  

  • 73. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria.
    Baldwin D; Chennakesavalu M; Gangemi A
    Surg Obes Relat Dis; 2019 Dec; 15(12):2123-2130. PubMed ID: 31711944
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
    Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
    World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.
    Wan T; Köhn N; Kröll D; Berzigotti A
    Obes Surg; 2021 Feb; 31(2):702-711. PubMed ID: 32959331
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies.
    Pedersen JS; Rygg MO; Serizawa RR; Kristiansen VB; Albrechtsen NJW; Gluud LL; Madsbad S; Bendtsen F
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501231
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan.
    Agarwal L; Aggarwal S; Shalimar ; Yadav R; Dattagupta S; Garg H; Agarwal S
    Obes Surg; 2021 Feb; 31(2):617-626. PubMed ID: 33052552
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.